Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 17.5
(-0.91%)
CNY 17.5
(-0.91%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 60.5 Million CNY | -12.39% |
| 2022 | 79.11 Million CNY | -30.1% |
| 2021 | 116.39 Million CNY | 23.01% |
| 2020 | 88.17 Million CNY | -24.75% |
| 2019 | 104.76 Million CNY | 6.24% |
| 2018 | 100.32 Million CNY | 39.11% |
| 2017 | 69.11 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -9.53 Million CNY | -429.76% |
| 2024 Q1 | 4.94 Million CNY | -51.68% |
| 2024 Q2 | -1.8 Million CNY | -133.96% |
| 2023 FY | - CNY | -12.39% |
| 2023 Q3 | 6.72 Million CNY | -55.45% |
| 2023 Q4 | 14.83 Million CNY | 120.43% |
| 2023 Q1 | 7.75 Million CNY | 230.33% |
| 2023 Q2 | 15.1 Million CNY | 94.66% |
| 2022 Q2 | 20.05 Million CNY | 30.05% |
| 2022 Q1 | 15.42 Million CNY | -39.92% |
| 2022 FY | - CNY | -30.1% |
| 2022 Q4 | 2.34 Million CNY | -86.84% |
| 2022 Q3 | 17.84 Million CNY | -11.05% |
| 2021 Q1 | 21.49 Million CNY | 108.75% |
| 2021 FY | - CNY | 23.01% |
| 2021 Q4 | 25.67 Million CNY | 54.69% |
| 2021 Q3 | 16.59 Million CNY | -47.28% |
| 2021 Q2 | 31.47 Million CNY | 46.42% |
| 2020 Q4 | -245.74 Million CNY | -188.26% |
| 2020 Q3 | 278.42 Million CNY | 579.43% |
| 2020 Q2 | 40.97 Million CNY | 44290.26% |
| 2020 Q1 | 92.31 Thousand CNY | 100.04% |
| 2020 FY | - CNY | -24.75% |
| 2019 Q4 | -247.04 Million CNY | 0.0% |
| 2019 FY | - CNY | 6.24% |
| 2018 FY | - CNY | 39.11% |
| 2017 FY | - CNY | 0.0% |